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A B S T R A C T
The aim of this research was to assess the clinical and biochemical efficacy of the octreotide in the treatment of pa-
tients with various functional gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study included 14 pa-
tients treated with octreotide for 6 months. They were diagnosed with VIPoma, glucagonoma, gastrinoma, medullary
thyroid carcinoma (solitary and as a part of MEN-II syndrome), pancreatic carcinoids (solitary and as a part of multiple
endocrine neoplasia type-1 syndrome-MEN-1 syndrome) and midgut carcinoids. The patients presented with Verner-
-Morrison, glucagonoma, Zollinger Ellison and carcinoid syndrome respectively. All had a metastatic disease at the time
of diagnosis and a positive octreoscan finding. Initially elevated chromogranin A (CgA) levels were detected in 11 (78.6%)
and elevated 5-hydroxyindolacetic acid (5-HIAA) levels in 8 (57.1%) patients. Symptomatic efficacy assessments were
made by diarrhea reductions during treatment course, and laboratory efficacy was assessed through changes in 5-HIAA
and CgA levels. Assessments were made initially and following 6 months of therapy. Median urinary 5-HIAA and the
number of stools decreased significantly (p=0.016 and p=0.009 respectively, p<0.05) while CgA levels had the decreas-
ing tendency but not statistically significant (p=0.14). There was a positive correlation between the 5-HIAA reduction
and the decrease in stool number at baseline and during treatment course (p<0.05). No correlation was observed between
5-HIAA and CgA levels and also there was no correlation between CgA reduction and symptomatic improvement. The re-
sults prove octreotide to be effective in reducing symptoms and biochemical markers associated with hypersecretory syn-
dromes of GEP-NETs.
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Introduction
Neuroendocrine tumors (NETs) are rare, heteroge-
neous and progressive tumors occurring in the pancreas,
parafollicular thyroid cells (medullary thyroid carcinoma,
MTC) and along the mucosa of the gastrointestinal sys-
tem (GEP-NETs). Their incidence ranges from 1–3 pa-
tients/100,000 population/year for carcinoids and is even
smaller for the pancreatic endocrine tumors (PET)1,2.
The term carcinoid is used for midgut serotonin produc-
ing tumors, while their location elsewhere is unusual.
Less than 10% of the carcinoids are associated with the
carcinoid syndrome, and it almost always implies liver
metastases. The syndrome comprises of diarrhea, flush-
ing, bronchospasm and eventually right-sided heart fail-
ure due to excess serotonin release3. Other GEP-NETs,
besides vasoactive substances and growth factors pro-
duce and release hormones responsible for the different
hypersecretory syndromes, sometimes more endanger-
ing than the tumor mass itself. The typical GEP-NET
hypersecretory syndromes include: Verner-Morrison syn-
drome resulting from the vasoactive intestinal polypep-
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tide (VIP) release, Zollinger-Ellison syndrome due to ex-
cess gastrin release, glucagonoma syndrome due to glucagon
release4,5. The long and short acting somatostatin ana-
logues have been shown to be effective in relieving flushing
and diarrhea associated with hypersecretory GEP-NET
syndromes, and indirect data suggest that somatostatin
analogs may also have a beneficial effect on patient
survival6. The aim of this analysis was to evaluate the
acute octreotide effects on symptom control (after 6
months of treatment) and biochemical markers (5-hydro-
xyindolacetic acid-5-HIAA and chromogranin A-CgA) of
neuroendocrine tumors.
Patients and Methods
Patients-the study included 14 GEP-NET patients
with hypersecretory syndromes including Zollinger-El-
lison (1 patient), glucagonoma (1 patient), Verner-Morri-
son (1 patient) and carcinoid syndrome (9 patients; 7 of
them with midgut carcinoids and 2 with pancreatic car-
cinoids) together with 2 patients receiving octreotide due
to medullary thyroid carcinoma (MTC). Two patients
had a tumor as a part of multiple endocrine neoplasia
syndromes type I and II. All patients were diagnosed and
treated in the Department of Endocrinology, Diabetes
and Metabolism University hospital »Sestre milosrdni-
ce« in the period including 1990–2005. The diagnosis of
the GEP-NET was confirmed patohistologically and/or
by imaging procedures including somatostatin receptor
scintigraphy (octreoscan). Nine of the patients were op-
erated prior to the octreotide treatment for the tumor
debulking; four patients were not operated as the exact
location of the primary could not be confirmed and one
patient with medullary thyroid carcinoma as a part of
MEN II syndrome refused the proposed operation due to
religious beliefs.
Treatment-after obtaining the GEP-NET diagnosis
and assessing the hypersecretory status the octreotide
treatment was initiated. All the patients diagnosed until
2000 received immediate-release octreotide subcutane-
ously titrated two to tree times daily till the relief of
symptoms up to maximum 200 µg and 3 patients diag-
nosed afterwards started with prolonged-release intra-
muscular octreotide in the dose of 20 mg monthly. In all
the patients the values of urinary 5-HIAA and CgA were
assessed prior to the treatment start (baseline value) and
then following 6 months of treatment. 5-HIAA was mea-
sured spectrophotometricaly with normal values below
72.8 nmol/L and for CgA a commercially available radio-
immunoassay kit (CIS Biointernational, Gif-sur-Yvette,
France) was used, the normal range being below 60
ng/ml.
Statistical Analysis-symptom frequency is presented
as a mean number of stools per day prior to treatment
and then after 6 months. For each patient mean symp-
tom frequency was calculated according to the data ob-
tained during patient/physician interview and included
data from 3 worse days prior to the treatment (baseline)
and on 6-month visit according to the between the visit
data. Nonparametric statistics was used, Wilcoxon signed
ranks test for the significance determination of changes
in a single parameter and Spearman’s test for the corre-
lation between different parameters. The level of signifi-
cance was set at p<0.005.
Results
All 14 patients (100%) had positive somatostatin re-
ceptor scintigraphy result (octreoscan) prior to the octre-
otide treatment. Nine patients (64.3%), with known pri-
mary were operated first for the tumor debulking, in four
(28.6%) patients primary tumor could not be detected
and metastases were not resectable so they were treated
with octreotide alone and 1 (7.1%) patient with known
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TABLE 1
BASELINE CHARACTERISTICS OF PATIENTS
Variable n Value
Age at diagnosis, yrs* 14 49.33
Age at treatment start, yrs* 14 53.8
Gender 14
male 12 (85.7%)
female 2 (14.3%)
Race 14
Caucasian 14 (100%)
Somatostatin receptor scintigraphy 14
positive 14 (100%)
negative
Type/site of GEP-NET 14
pancreatic endocrine tumor (PET) 5 5 (35.7%)
VIPoma 1 (7.1%)
gastrinoma 1 (7.1%)
glucagonoma 1 (7.1%)
carcinoid 2 (14.3%)
gastrointestinal NET 7 7 (50%)
foregut carcinoid 0
midgut carcinoid 7 (50%)
hindgut carcinoid 0
medullary thyroid carcinoma (MTC) 2 2 (14.3%)
Presence of MEN syndromes 11
MEN 1 1 (7.1%)
MEN 2 1 (7.1%)
Prior GI surgery 9 (64.3%)
Type of octreotide 14
immediate-release 11(78.6 %)
prolonged-release 3 (21.4%)
Initial 5-HIAA elevation 8 (57.1%)
Initial CgA elevation 11 (78.6%)
*data presented as an average
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primary refused the proposed operation due to religious
beliefs. The most common tumor site was midgut (64.3%),
followed by pancreatic NET (28.6%) and MTC (14.3%).
Average age at diagnosis was 49.33 years with youngest
patient being diagnosed at the age of 12 and oldest at the
age of 69. Octreotide treatment was initiated after aver-
age of 4.46 years following the diagnosis. The mean age
of treatment start was 53.8 years. Above normal levels of
5-HIAA were recorded for 8 patients (57.1%) and above
normal values of CgA for 11 (78.6%) patients initially
(Table 1).
Statistically significant reduction in 5-HIAA (p=0.016)
and diarrhea (p=0.09) was observed after 6-months of
treatment. Although CgA levels had the decreasing ten-
dency during treatment course, the reduction was not
statistically significant (p=0.140). The correlation was
noticed between the number of stools and levels of 5-
-HIAA initially (Figure 1) and there was also a positive
correlation between the reduction of 5-HIAA and symp-
tomatic improvement during the treatment course (p<
0.05, Figure 2). The same correlation was not statistically
significant for the CgA (p=0.024). There was also no cor-
relation noticed between the CgA and 5-HIAA levels.
Discussion
This single centre analysis has repeatedly proven the
octreotide effectiveness in the treatment of symptoms as-
sociated with different hypersecretory neuroendocrine
tumors. As NETs are rare, the data concerning biological
treatment, especially its biochemical effects, resulting
from tumor cell apoptosis, are still inconclusive7,8. After
six months of treatment (the acute treatment phase) the
symptomatic improvement (measured through diarrhea
reduction) was significant both clinically and statisti-
cally. The diarrhea was chosen as a target symptom as it
seemed most incapacitating and imposed the greatest
burden on normal social life of patients. Among other
hypersecretory symptoms present (flushing, wheezing) it
was also the easiest symptom to quantify. There are sev-
eral underlying mechanisms contributing to the diarrhea
in NETs, among them tumor burden itself with biochem-
ical substances such as serotonin, and postoperative ma-
labsorption of bile acids and fat in surgically treated
NET patients8,9. The good symptomatic response was
also noticed in similar studies13,14, although the reduc-
tion in stool number was somewhat greater in our pa-
tients. This is most probably because all our patients
were, unlike patients in other studies, octreotide naïve,
and also 64.3% of them (hence the number of surgically
treated patients is somewhat greater in other studies)
had a pre-octreotide treatment GI operation, which could
adversely contribute to diarrhea. The maintenance of the
positive response to octreotide remains to be seen during
chronic treatment course, but according to our experi-
ence and results from other authors it is likely to dimin-
ish over the years of use, both clinically and biochemi-
cally. The exact reason for this tachyphylaxis is still
unknown, but it seems to be more evident in patients re-
ceiving immediate-release octreotide than in patients on
prolonged-release preparations. As in other similar stud-
ies, our patient sample was also small, so in order to de-
termine the biochemical or molecular ground of the men-
tioned, more studies and meta analysis will be needed in
future.
In addition to improvement in symptoms, levels of
5-HIAA reduced significantly while CgA levels, although
showing the decreasing tendency, did not differ signifi-
cantly. The similar biochemical improvement was also
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Fig. 1. Baseline correlation between the 5-HIAA and stool number.
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Fig. 2. Correlation between 5-HIAA and stool number after
6-months of treatment.
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observed in study by Ruszniewski7 and like in our study
it was more evident for the 5-HIAA than CgA. Baseline
levels of 5-HIAA and CgA differed from the mentioned
study and were slightly more positive for the 5-HIAA
than CgA7.
There was a positive correlation between baseline
symptom severity and 5-HIAA level. Also, the significant
reduction of number of stools per day during treatment
course was noticed parallel to the reduction of the 5-
-HIAA levels. This symptomatic improvement is proba-
bly dependant on the direct effect the octreotide has on
tumor metastases and their secretory activity measured
through serotonin and its metabolite reduction7–11. Why
the same correlation was not observed for the CgA and
symptom severity still remains unanswered. According
to all the data, octreotide is effective and safe in the
treatment of hypersecretory symptoms of different neu-
roendocrine tumors11–15. It also has a beneficial effect on
biochemical markers, somewhat greater on 5-HIAA than
on CgA, a more ubiquitary NET marker.
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NA[E ISKUSTVO S OKTREOTIDOM U LIJE^ENJU PACIJENATA S RAZLI^ITIM
FUNKCIONALNIM NEUROENDOKRINIM TUMORIMA PROBAVNOG SUSTAVA I GU[TERA^E
S A @ E T A K
Cilj ovog istra`ivanja bila je procjena klini~ke i biokemijske u~inkovitosti oktreotida primijenjenog u lije~enju bo-
lesnika s razli~itim funkcionalnim neuroendokrinim tumorima probavnog sustava i gu{tera~e (GEP-NET). U ispiti-
vanje je bilo uklju~eno 14 bolesnika lije~enih zbog VIPoma, glukagonoma, gastrinoma, medularnog karcinoma {tit-
nja~e, karcinoida gu{tera~e te karcinoida embriogenetskog podrijetla srednjeg crijeva. Pacijenti su pra}eni tijekom 6
mjeseci, a klini~ki su se prezentirali Verner-Morrisonovim, Zollinger-Ellisonovim, karcinoidnim te sindromom suvi{ka
glukagona. U trenutku postavljanja dijagnoze svi su bolesnici imali pro{irenu bolest te je kod svih bio pozitivan nalaz
oktreoscana. Inicijalno povi{ene vrijednosti kromogranina A (CgA) na|ene su u 11 (78.6%), a 5-HIAA u 8 (57.1%) boles-
nika. Simptomatski u~inak procjenjivan je redukcijom broja stolica, a biokemijski u~inak kroz promijene u razini se-
rumskih vrijednosti CgA i 5-HIAA u 24-satnom urinu na po~etku lije~enja te {est mjeseci trajanja terapije oktreotidom.
Na kraju ispitivanja do{lo je do zna~ajne redukcije vrijednosti 5-HIAA i broja stolica (p=0.016 i p=0.009), dok je kod
CgA primije}ena regresivna dinamika, no bez statisti~ke zna~ajnosti (p=0.14). Zamije}ena je pozitivna korelacija iz-
me|u redukcije 5-HIAA i smanjenja broja stolica na po~etku ispitivanja te nakon 6 mjeseci lije~enja (p<0.05). Nije
zabilje`ena korelacija izme|u vrijednosti 5-HIAA i CgA kao niti CgA i simptomatskog pobolj{anja. Pripravci oktreotida
pokazali su se u~inkovitim u redukciji simptoma ali i biokemijskih biljega razli~itih funkcionalnih GEP-NETa.
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